News | November 05, 2024
Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
Strengthening focus in Alzheimer's disease and neuroscience pipeline
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
The acquisition will strengthen the overall company’s position as leading global CRO services partner
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
he company will focus on production of any pharmaceutical and biotechnological products
Developed in consultation with clinicians and patients for an enhanced user experience
Subscribe To Our Newsletter & Stay Updated
